Specialty Digest

Global English editionLearners’ Study Dashboard — in development
The Knowledge Library for All

World Leprosy Day

Leprosy is curable. The harder work is ending the fear and delay that still cost people their health and dignity.

Share
Link copied

All international days

Date
Last Sunday of January (January 25 in 2026, January 31 in 2027)
Supported by
World Health Organization (WHO)
Guiding plan
Global Leprosy Strategy 2021 to 2030
2026 theme
Leprosy is curable, the real challenge is stigma

Leprosy is among the oldest diseases in human memory, and among the most misunderstood. It is curable. It is not easily caught. Yet the word still carries a fear that has often done more lasting harm to people than the bacterium itself. World Leprosy Day, held on the last Sunday of January, asks the world to separate the disease from the myth. For 2026, the theme announced by WHO was “Leprosy is curable, the real challenge is stigma.” The day sits alongside World Neglected Tropical Diseases Day, because leprosy belongs to the group of diseases that affect the poorest communities and attract the least attention.

What leprosy is, and what it is not

Leprosy, also called Hansen’s disease, is caused by a bacterium, Mycobacterium leprae. It mainly affects the skin and the peripheral nerves, the long nerves that carry feeling and movement to the hands, feet and face. The most common early sign is a pale or reddish patch of skin where feeling is lost. Nerves can also thicken and weaken muscles. WHO describes three signs doctors look for: a skin patch with definite loss of sensation, a thickened nerve with numbness or weakness, and bacteria seen in a skin smear.

The disease is believed to pass through droplets from the nose and mouth of an untreated person, after long and close contact. It does not spread through casual contact, and a person stops transmitting once treatment begins. Left untreated, however, nerve damage can become permanent. Numb hands and feet are injured without notice, wounds go unseen, and over time fingers, toes and eyesight can be lost. The disability, not the infection, is what the world remembers and fears.

A cure that changed everything

The turning point was multidrug therapy, or MDT, a combination of three antibiotics: dapsone, rifampicin and clofazimine. WHO recommended it in 1981. Treatment lasts 6 months for milder cases and 12 months for more advanced ones. In the mid-1980s, more than 5 million cases were on record worldwide. WHO has supplied MDT free of charge to every patient since 2000, first with funding from The Nippon Foundation and, since that year, with medicine donated by Novartis. The two organizations extended their agreement for another five years, 2026 to 2030.

Leprosy cases then and nowMore than 5 million cases in the mid-1980s compared with 172,717 new cases reported in 2024. Leprosy cases, then and now Mid-1980s: over 5 million cases 2024: 172,717 new cases reported about 3% The two bars use different measures: cases on recordthen, new cases reported in a year now.
Scale of the caseload, then and now. Sources: WHO leprosy message, January 2026 (2024 count and 1980s figure).

The numbers behind the day

In 2024, 172,717 new cases were reported to WHO by 133 countries. Of the 188 countries, areas and territories that submitted data, 55 reported no cases at all. WHO’s fact sheet puts the usual yearly toll at around 200,000 new cases and notes that most detections come from the South-East Asia Region. Three countries, Brazil, India and Indonesia, each reported more than 10,000 new cases in 2024, and twelve others reported between 1,000 and 10,000. WHO also notes that leprosy was eliminated as a public health problem globally in 2000, meaning fewer than one case per 10,000 people, and in most countries by 2010.

Countries by number of new cases, 202455 countries reported no cases, 12 reported 1,000 to 10,000, and 3 reported more than 10,000. How cases are spread, 2024 Countries reporting no casesCountries reporting 1,000 to 10,000Over 10,000: Brazil, India, Indonesia 55123 Based on 188 countries, areas and territories reporting.
Number of countries by new cases reported in 2024. Source: WHO leprosy fact sheet and WHO news release, January 2026.
  • 5.4%of new cases in 2024 were children under 15
  • 5.3%of new cases in 2024 already had visible disability (grade 2)
  • 133countries reported new cases in 2024
  • 55reporting countries had zero cases in 2024

The two percentages deserve attention. WHO’s message for the day says that cases among children and cases with visible disability point to ongoing transmission in communities and to diagnosis that comes too late. Every child with leprosy was infected by someone who was not yet treated. Every visible disability is a sign that the disease went unrecognized for years.

Example 1: the cost of waiting. Suppose a farmer notices a numb pale patch on her arm but the nearest clinic is a day’s travel away, so she waits two years. By then the nerve is damaged and her hand has weakened. Had she been treated in the first months, six months of free tablets might have prevented the disability. The numbers are made up and round, but the pattern is the one WHO describes: late diagnosis turns a curable infection into a lasting disability.

Stigma, the harder problem

Medicine has largely solved the infection. Fear has not been solved so easily. People affected by leprosy, and their families, have long faced exclusion from work, school, marriage and community life, sometimes even after they are cured. WHO’s message for 2026 states that stigma can be more problematic than the disease itself and can persist after treatment.

The United Nations has addressed this directly. On December 21, 2010, the General Assembly adopted resolution 65/215, “Elimination of discrimination against persons affected by leprosy and their family members.” It took note with appreciation of a set of principles and guidelines drawn up under the Human Rights Council (document A/HRC/15/30) and encouraged governments, UN bodies, national human rights institutions and other actors to give them due consideration when making policy. The resolution also encouraged hospitals, schools, universities, religious groups, businesses and the media to do the same. Fear, in other words, is treated as a matter of human rights, not only of public health.

Example 2: a school’s choice. Imagine a village school where a cured student is asked to sit apart because parents are afraid. A teacher who explains, with the facts above, that the child is not infectious and that treatment ended the risk, can reverse the exclusion in a single morning. The scenario is illustrative, but it shows why the 2026 theme puts stigma on the same footing as the cure.

Stopping the next case

Treating patients is not enough to stop the chain of infection, because people can carry the disease for years before signs appear. WHO’s strategy for 2021 to 2030, titled “Towards zero leprosy,” sets a vision of zero infection and disease, zero disability, and zero stigma and discrimination. It rests on four pillars: country-owned plans to reach zero leprosy, prevention together with active case finding, management of the disease and its complications, and a fight against stigma that protects human rights.

One practical tool is post-exposure prophylaxis. When a case is found, health workers screen the person’s close contacts and offer them a single dose of rifampicin to lower their chance of developing the disease. The agreement with Novartis for 2026 to 2030 covers funding for procuring and distributing single-dose rifampicin as well as MDT and clofazimine. Clofazimine also treats lepra reactions, sudden and severe inflammation that can cause disability if left untreated.

From first sign to preventionFour steps: spot the signs, confirm the diagnosis, treat with multidrug therapy, and protect close contacts with a single dose of rifampicin. From first sign to prevention 1. Spot the signsNumb pale or reddish skin patch 2. ConfirmNerve check or skin smear 3. Treat with MDTFree, 6 or 12 months 4. Protect close contactsScreening and one dose of rifampicin Steps follow WHO’s fact sheet and 2026 news release.
The path from first sign to prevention. Source: WHO leprosy fact sheet, January 2026.

Example 3: why screening pays. Suppose a clinic finds one new case and screens 20 household and neighborhood contacts, giving each one dose. If even a few of those people would otherwise have fallen ill years later, one afternoon of work has prevented several future cases and their disabilities. The figures are round and illustrative, not a measured result, but they capture the logic of the strategy: find the case, then find the people around it.

How the day is marked

The day is observed on the last Sunday of January each year. WHO offices and partners issue messages, health ministries run awareness and screening activities, and people affected by leprosy share their own stories. In 2026, WHO Goodwill Ambassador for Leprosy Elimination Yohei Sasakawa marked 25 years in that role, and his message that year called for renewed attention to the 2010 UN resolution, noting that interest in it has waned in recent years. The most useful way to take part is simple: learn the facts, share them, and treat anyone affected as the neighbor, colleague or classmate they are.

Key Takeaways

  1. Leprosy is curable. Three-drug MDT, given free by WHO, cures it in 6 to 12 months.
  2. It is not easily caught. It spreads through close, prolonged contact with an untreated person, and treatment ends transmission.
  3. Progress is large but unfinished. Cases fell from over 5 million in the mid-1980s to 172,717 new cases in 2024.
  4. Late diagnosis is the warning sign. In 2024, 5.4% of new cases were children and 5.3% already had visible disability.
  5. Stigma outlasts the disease. UN resolution 65/215 treats discrimination against affected people as a human rights concern.
  6. Prevention is within reach. Screening contacts and giving one dose of rifampicin is a core tool of the 2021 to 2030 strategy.
  7. You can help. Accurate words, early care for any numb skin patch, and equal treatment for people affected all make a difference.

How solid is this? Case counts are as reported to WHO by countries and are updated each year, so later figures may differ. The percentages for children and disability are shares of the 172,717 cases reported for 2024. The comparison with the mid-1980s uses two different measures, cases on record then and new cases reported now, so it shows scale rather than a rate of decline. The three worked examples use round, made-up numbers to show an idea. See also the International Days hub and the International Days Calendar.

About the AuthorSpecialty Digest Editorial TeamEditorial StaffReporting and analysis from the Specialty Digest editorial team.
Share
Link copied